GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year’s End
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth and GVK Biosciences were cleared in May to restart the Indian trials after no links were found between the alleged death of an infant in a Bangalore-based hospital and the trials.